The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.

ABSTRACT:

Objective

To examine the long-term efficacy and safety of the intravitreal 0.2-μg/day fluocinolone acetonide implant (FAi) to treat noninfectious uveitis (NIU) of the posterior segment (PS).

Design

Three-year, phase III, multicenter, randomized, double-masked, controlled, prospective study (clinicaltrials.gov, NCT02746991).

Participants

Overall, 153 patients in India with NIU-PS in ≥ 1 eye (with or without anterior uveitis) for ≥ 1 year who had ≥ 2 separate recurrences of uveitis requiring ocular injections or systemic therapy in the prior 12 months.

Methods

Patients were randomized 2:1 for baseline FAi or sham injection and monitored for main outcome measures.

Main outcome measures

Incidence and timing of uveitis recurrence, use of adjunctive therapy, b

SUBMITTER: Biswas J 

PROVIDER: S-EPMC10630780 | biostudies-literature | 2024 Jan-Feb

REPOSITORIES: biostudies-literature